![Robert E. Campbell](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Robert E. Campbell
Direktor/Vorstandsmitglied bei
The Cancer Institute of New Jersey
Profil
Dr. Robert E.
Campbell is Chairman at The Cancer Institute of New Jersey and an Advisory Board Member at Plebys International LLC.
He has been a Director of Barrier Therapeutics, Inc. since September 2004.
He is also on the Advisory Board of Plebys International.
Previously, he was Vice Chairman of Johnson & Johnson from April 1989 to January 1995.
He held various positions with Johnson & Johnson, including Vice Chairman of the Executive Committee, Chairman of the Professional Sector and Chief Financial Officer.
He is Chairman of the Board of Advisors for The Cancer Institute of New Jersey and a past Chairman and present Board Member of The Robert Wood Johnson Foundation and Fordham University.
Dr. Campbell received a BS from Fordham University and an MBA from Rutgers University.
Aktive Positionen von Robert E. Campbell
| Unternehmen | Position | Beginn |
|---|---|---|
The Cancer Institute of New Jersey
 The Cancer Institute of New Jersey Hospital/Nursing ManagementHealth Services Operates cancer center | Direktor/Vorstandsmitglied | - |
Rutgers State University of New Jersey
 Rutgers State University of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Direktor/Vorstandsmitglied | - |
Rutgers University Foundation
 Rutgers University Foundation Investment Trusts/Mutual FundsMiscellaneous Provides fund raising services | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Robert E. Campbell
| Unternehmen | Position | Ende |
|---|---|---|
The Robert Wood Johnson Foundation
 The Robert Wood Johnson Foundation Investment Trusts/Mutual FundsMiscellaneous RWJF seeks to earn an investment return that, over time, equals or exceeds the sum of its annual spending, as a percentage of the Foundation’s assets plus the rate of inflation. This balance of investment return and spending is designed to spread risk and promote a steady, stable flow of support for our grantees. Since the firm focuses their philanthropy on meeting many of the nation’s most critical health challenges, they seek to avoid investments in companies whose businesses are predominantly related to the manufacture, sale, or distribution of firearms, alcohol, cannabis, or tobacco-related products. | Corporate Officer/Principal | 31.12.2008 |
Barrier Therapeutics, Inc.
 Barrier Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceutical products in the field of dermatology | Direktor/Vorstandsmitglied | 04.08.2008 |
| JOHNSON & JOHNSON | Finanzdirektor/CFO | 01.01.1995 |
US Department of Defense (District of Columbia)
 US Department of Defense (District of Columbia) SovereignGovernment Operates and maintains defense departments | Corporate Officer/Principal | 31.12.1958 |
Mesoblast, Inc.
 Mesoblast, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes biopharmaceutical products | Direktor/Vorstandsmitglied | - |
Ausbildung von Robert E. Campbell
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
89
Beziehungen ersten Grades
9
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 9 |
|---|---|
Johnson & Johnson
 Johnson & Johnson Pharmaceuticals: MajorHealth Technology Operates as an investment holding company with interests in health care products | Health Technology |
The Robert Wood Johnson Foundation
The Robert Wood Johnson Foundation Investment Trusts/Mutual FundsMiscellaneous RWJF seeks to earn an investment return that, over time, equals or exceeds the sum of its annual spending, as a percentage of the Foundation’s assets plus the rate of inflation. This balance of investment return and spending is designed to spread risk and promote a steady, stable flow of support for our grantees. Since the firm focuses their philanthropy on meeting many of the nation’s most critical health challenges, they seek to avoid investments in companies whose businesses are predominantly related to the manufacture, sale, or distribution of firearms, alcohol, cannabis, or tobacco-related products. | Miscellaneous |
Barrier Therapeutics, Inc.
Barrier Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceutical products in the field of dermatology | Health Technology |
Mesoblast, Inc.
Mesoblast, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes biopharmaceutical products | Health Technology |
Rutgers State University of New Jersey
Rutgers State University of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fordham University
 Fordham University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
US Department of Defense (District of Columbia)
US Department of Defense (District of Columbia) SovereignGovernment Operates and maintains defense departments | Government |
The Cancer Institute of New Jersey
The Cancer Institute of New Jersey Hospital/Nursing ManagementHealth Services Operates cancer center | Health Services |
Rutgers University Foundation
Rutgers University Foundation Investment Trusts/Mutual FundsMiscellaneous Provides fund raising services | Miscellaneous |
Wählen Sie MarketScreener 
